Reversal agents for use with direct and indirect anticoagulants

American Journal of Health-System Pharmacy

Volumn 73, Issue 10, 2016, Pages S27-S48

  Smythe, Maureen A ^a,b   Trujillo, Toby ^c   Fanikos, John ^d  

^a Beaumont Health ^*  (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIDOTE; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; CIRAPARANTAG; DABIGATRAN; EDOXABAN; ENOXAPARIN; FIBRIN; FIBRINOGEN; FONDAPARINUX; HEPARIN; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; ARGININE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BLOOD CLOTTING TEST; CLINICAL PHARMACY; CONSTIPATION; DELIRIUM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART RIGHT VENTRICLE FAILURE; HEMOSTASIS; HUMAN; HYDROGEN BOND; INTERNATIONAL NORMALIZED RATIO; LUNG EDEMA; NONHUMAN; PATIENT SELECTION; PHARMACIST; PNEUMONIA; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; HEMORRHAGE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; ARGININE; DABIGATRAN; FACTOR XA; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PIPERAZINES; RECOMBINANT PROTEINS;

EID: 84968799876     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150959     Document Type: Article

References (71)

1. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran etexilate mesylate) prescribing information. http://docs.boehringer-ingelheim. com/Prescribing%20Information/PIs/ Pradaxa/Pradaxa.pdf (accessed 2016 Jan 14).
2. Bristol-Myers Squibb. Eliquis (apixaban) prescribing information. http://packageinserts.bms.com/pi/ pi-eliquis.pdf (accessed 2015 Jul 30).
3. Daiichi Sankyo, Inc. Savaysa (edoxaban) prescribing information. http:// dsi.com/prescribing-informationportlet/getPIContent?productName =Savaysa&inline=true (accessed 2015 Jul 30).
4. Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) prescribing information. https://www.xareltohcp.com/ shared/product/xarelto/prescribinginformation.pdf (accessed 2015 Jul 30).
5. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955-62.
6. Liew A, O'Donnell M, Douketis J. Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials. J Thromb Haemost. 2014; 12:1419-24.
7. Wu C, Alotaibi GS, Alsaleh K, Sean McMurtry M. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review. Thromb Res. 2014; 134:627-32.
8. Institute For Safe Medication Practices. Update on anticoagulants. http://www. ismp.org/quarterwatch/pdfs/2012Q2. pdf (accessed 2015 Aug 12).
9. Smythe MA, Forman MJ, Bertran EA et al. Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients. J Thromb Thrombolysis. 2015; 40:280-7.
10. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015; 35:1056-65.
11. Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012; 163:13-9 e1.
12. Huisman MV, Diener H-C, Dubner SJ et al. Global registry on longterm oral antithrombotic treatment in patients with atrial fibrillation: final baseline characteristics of the GLORIA-AF phase II patient cohort. http://congress365.escardio.org/ Search-Results?vgnextkeyword=GL ORIA+AF#.VfqAVmxwaUk (accessed 2015 Sept 17).
13. Beyer-Westendorf J, Ebertz F, Förster K et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015; 113:1247-57.
14. Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015; 131:157-64.
15. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace. 2015:[Epub ahead of print].
16. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015; 113:931-42.
17. Proietti M, Lip GY. Antidotes to nonvitamin K oral anticoagulants: necessary or not? Expert Opin Pharmacother. 2015; 16:1573-6.
18. Vanden Daelen S, Peetermans M, Vanassche T et al. Monitoring and reversal strategies for new oral anticoagulants. Expert Rev Cardiovasc Ther. 2015; 13:95-103.
19. Sarich TC, Seltzer JH, Berkowitz SD et al. Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am Heart J. 2015; 169:751-7.
20. Boehringer Ingelheim Inc. Praxbind prescribing information. http://www. accessdata.fda.gov/drugsatfda-docs/ label/2015/761025lbl.pdf (accessed 2015 Oct 20).
21. Portola Pharmaceuticals. Portola Pharmaceuticals receives breakthrough therapy designation from FDA for andexanet alfa (PRT4445&z.ast;), investigational factor Xa inhibitor antidote. http://investors.portola.com/ phoenix.zhtml?c=198136&p=irolnewsroomArticle&ID=1879666 (accessed 2015 Aug 10).
22. Portola Pharmaceuticals. Portola Pharmaceuticals receives FDA orphan drug designation for andexanet alfa, its breakthrough-designated factor Xa inhibitor antidote. http://investors.portola.com/ phoenix.zhtml?c=198136&p=irolnewsroomArticle&ID=2020507 (accessed 2015 Aug 12).
23. Portola Pharmaceuticals. Portola Pharmaceuticals submits andexanet alfa's BLA to US FDA. http://investors.portola.com/ phoenix.zhtml?c=198136&p=irolnewsroomArticle&ID=2123971 (accessed 2016 Jan 14).
24. Perosphere. Perosphere receives FDA fast track designation for investigational anticoagulant reversal agent PER977. http://perosphere.com/ documents/PerosphereFDAFastTrack. pdf (accessed 2015 Aug 12).
25. Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013; 121:3554-62.
26. Arellano-Rodrigo E, Lopez-Vilchez I, Molina P et al. Idarucizumab fully restores dabigatran-induced alterations on platelet and fibrin deposition on damaged vessels: studies in vitro with circulating human blood. Blood. 2014; 124:Abstract.
27. Grottke O, van Ryn J, Spronk HM, Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care. 2014; 18:R27.
28. Grottke O, Honickel M, van Ryn J et al. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. 2015; 66:1518-9.
29. Glund S, Moschetti V, Norris S et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015; 113:943-51.
30. Glund S, Stangier J, Schmohl M et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015; 386:680-90.
31. Pollack CV, Jr., Reilly PA, Bernstein R et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015; 114:198-205.
32. Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014; 63:321-8.
33. Glund S, Stangier J, Schmohl M et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014; 124:344.
34. Pollack CV, Jr., Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373:511-20.
35. Sarode R, Milling TJ, Jr., Refaai MA et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013; 128:1234-43.
36. Pollack CV, Jr., Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. http://www.nejm.org/doi/ suppl/10.1056/NEJMoa1502000/ suppl-file/nejmoa1502000-protocol. pdf (accessed 2015 Aug 18).
37. Aniara Diagnostica LLC. Premarket Notification Section 510(k). Hemoclot Quanti V-L; Factor V-L, Calibrator; Biophen V-L Cal (Undiluted); Biophen Act PC-r Control Plasma. http:// www.accessdata.fda.gov/cdrh-docs/ pdf8/k083729.pdf (accessed 2016 Jan 15).
38. Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19:446-51.
39. Shah N, Rattu MA. Reversal agents for anticoagulants: focus on andexanet alfa. American Medical Student Research Journal. 2014; 1:16-28.
40. Crowther M, Kitt M, Lorenz T et al. A phase 2 randomized, doubleblind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost. 2013; 11:30. AS20.1.
41. Crowther M, Kitt M, McClure M et al. Randomized, double-blind, placebocontrolled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors. Arterioscler Thromb Vasc Biol. 2013; 33:A10.
42. Crowther M, Vandana M, Michael K et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. 55th American Society of Hematology annual meeting and exposition. New Orleans, LA, USA: American Society of Hematology; 2013:3636.
43. Yeh CH, Fredenburgh JC, Weitz JI. The real decoy: an antidote for factor Xa-directed anticoagulants. Circ Res. 2013; 113:954-7.
44. Crowther M, Lu GM, Conley P et al. Reversal of factor Xa inhibitorsinduced anticoagulation in healthy subjects by andexanet alfa. Crit Care Med. 2014; 42:A455.
45. Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. 2015; 35:198-207.
46. Crowther M, Levy GG, Lu GM et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood. 2014; 124:4269.
47. Crowther M, Levy G, Lu G et al. Reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for direct and indirect fXa inhibitors-a phase 2 randomized, double-blind, placebo-controlled trial. J Thromb Haemost. 2014; 12:7. COA01.
48. Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015; 373:2413-24.
49. Portola Pharmaceuticals. A study in patients with acute major bleeding to evaluate the ability of andexanet alfa to reverse the anticoagulation effect of direct and indirect oral anticoagulants. https://www.clinicaltrials.gov/ ct2/show/NCT02329327?term=and exanet+alfa&rank=3 (accessed 2016 Jan 14).
50. Costin J, Ansell J, Bakhru S et al. The new oral anticoagulants: clinical use and reversal agent development. ISBT Science Series. 2015; 10:324-31.
51. Laulicht B, Bakhru S, Jiang X et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. J Thromb Haemost. 2013; 11:75.
52. Das A, Liu D. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015; 4:25.
53. United States National Institutes of Health. Search results for PER977. https://www.clinicaltrials.gov/ct2/ results?term=per977 (accessed 2015 Aug 13).
54. Bakhru S, Laulicht B, Jiang X et al. A synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation. 2013; 128:A18809.
55. Sullivan DW, Jr., Gad SC, Laulicht B et al. Nonclinical safety assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol. 2015; 34:308-17.
56. Laulicht B, Bakhru S, Lee C et al. Small molecule antidote for anticoagulants. Circulation. 2012; 126:A11395.
57. Costin JC, Laulicht B, Bakhru S, Steiner S. PER977 reverses low molecular weight heparin in addition to IIa and Xa new oral anticoagulants. J Am Coll Cardiol. 2015; 65:A2056.
58. Ansell JE, Bakhru SH, Laulicht BE et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371:2141-2.
59. Laulicht B, Bakhru S, Steiner S et al. PER977 (ciraparantag) reverses edoxaban anticoagulation at steady state and has no effect on re-anticoagulation at the next scheduled dose. Eur Heart J. 2015; 36:859-60.
60. Dager WE. Developing a management plan for oral anticoagulant reversal. Am J Health Syst Pharm. 2013; 70:S21-31.
61. Weitz JI, Pollack CV, Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015; 114:1113-26.
62. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012; 126:2428-32.
63. CADTH. Antidote treatments for the reversal of direct oral anticoagulants. https://www.cadth.ca/antidotetreatments-reversal-direct-oralanticoagulants (accessed 2015 Aug 13).
64. van Es N, Coppens M, Schulman S et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124:1968-75.
65. Logan AC, Yank V, Stafford RS. Offlabel use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011; 154:516-22.
66. Bauer KA. Targeted anti-anticoagulants. N Engl J Med. 2015; 373:569-71.
67. Phillips KW, Wittkowsky AK. Survey of pharmacist-managed inpatient anticoagulation services. Am J Health Syst Pharm. 2007; 64:2275-8.
68. Reardon DP, Atay JK, Ashley SW et al. Implementation of a hemostatic and antithrombotic stewardship program. J Thromb Thrombolysis. 2015; 40:379-82.
69. Padron M, Miyares MA. Development of an anticoagulation stewardship program at a large tertiary care academic institution. J Pharm Pract. 2015; 28:93-8.
70. Olson DP, Windish DM. Communication discrepancies between physicians and hospitalized patients. Arch Intern Med. 2010; 170:1302-7.
71. Tully MP, Ashcroft DM, Dornan T et al. The causes of and factors associated with prescribing errors in hospital inpatients: a systematic review. Drug Saf. 2009; 32:819-36.